Trial Profile

Phase 2 Study of ITCA 650 in Subjects With Type 2 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Exenatide (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Intarcia Therapeutics

Most Recent Events

05 Oct 2012 Results from weeks 13-24 presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
03 Oct 2012 An analysis of data supporting dose selection for the global phase III programme of exenatide (12- and 24-week outcomes) was reported in an Intarcia Therapeutics media release.
28 Sep 2012 Results from the parent study will be presented at the 48th Annual Meeting of the European Association for the Study of Diabetes, according to a Intarcia Therapeutics media release. They will be presented at EASD.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com